Logo image of AXSM

AXSOME THERAPEUTICS INC (AXSM) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:AXSM - US05464T1043 - Common Stock

149.22 USD
+1.18 (+0.8%)
Last: 12/5/2025, 8:04:07 PM
149.22 USD
0 (0%)
After Hours: 12/5/2025, 8:04:07 PM
Fundamental Rating

2

Taking everything into account, AXSM scores 2 out of 10 in our fundamental rating. AXSM was compared to 192 industry peers in the Pharmaceuticals industry. AXSM has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, AXSM is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AXSM had negative earnings in the past year.
AXSM had a negative operating cash flow in the past year.
In the past 5 years AXSM always reported negative net income.
In the past 5 years AXSM always reported negative operating cash flow.
AXSM Yearly Net Income VS EBIT VS OCF VS FCFAXSM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

Looking at the Return On Assets, with a value of -34.30%, AXSM is in line with its industry, outperforming 48.44% of the companies in the same industry.
Looking at the Return On Equity, with a value of -311.32%, AXSM is doing worse than 75.00% of the companies in the same industry.
Industry RankSector Rank
ROA -34.3%
ROE -311.32%
ROIC N/A
ROA(3y)-49.23%
ROA(5y)-70.3%
ROE(3y)-266.63%
ROE(5y)-345.24%
ROIC(3y)N/A
ROIC(5y)N/A
AXSM Yearly ROA, ROE, ROICAXSM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

1.3 Margins

AXSM has a better Gross Margin (91.86%) than 93.75% of its industry peers.
AXSM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.86%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AXSM Yearly Profit, Operating, Gross MarginsAXSM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

2

2. Health

2.1 Basic Checks

AXSM does not have a ROIC to compare to the WACC, probably because it is not profitable.
AXSM has more shares outstanding than it did 1 year ago.
AXSM has more shares outstanding than it did 5 years ago.
AXSM has a worse debt/assets ratio than last year.
AXSM Yearly Shares OutstandingAXSM Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AXSM Yearly Total Debt VS Total AssetsAXSM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

AXSM has an Altman-Z score of 4.99. This indicates that AXSM is financially healthy and has little risk of bankruptcy at the moment.
AXSM's Altman-Z score of 4.99 is fine compared to the rest of the industry. AXSM outperforms 74.48% of its industry peers.
AXSM has a Debt/Equity ratio of 2.61. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 2.61, AXSM is doing worse than 79.69% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 2.61
Debt/FCF N/A
Altman-Z 4.99
ROIC/WACCN/A
WACC9.22%
AXSM Yearly LT Debt VS Equity VS FCFAXSM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

AXSM has a Current Ratio of 1.57. This is a normal value and indicates that AXSM is financially healthy and should not expect problems in meeting its short term obligations.
AXSM has a Current ratio of 1.57. This is in the lower half of the industry: AXSM underperforms 69.79% of its industry peers.
A Quick Ratio of 1.50 indicates that AXSM should not have too much problems paying its short term obligations.
AXSM has a Quick ratio of 1.50. This is in the lower half of the industry: AXSM underperforms 62.50% of its industry peers.
Industry RankSector Rank
Current Ratio 1.57
Quick Ratio 1.5
AXSM Yearly Current Assets VS Current LiabilitesAXSM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 28.48% over the past year.
Looking at the last year, AXSM shows a very strong growth in Revenue. The Revenue has grown by 65.83%.
EPS 1Y (TTM)28.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.85%
Revenue 1Y (TTM)65.83%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%63.22%

3.2 Future

Based on estimates for the next years, AXSM will show a very strong growth in Earnings Per Share. The EPS will grow by 39.12% on average per year.
The Revenue is expected to grow by 46.68% on average over the next years. This is a very strong growth
EPS Next Y38.6%
EPS Next 2Y46.26%
EPS Next 3Y49.73%
EPS Next 5Y39.12%
Revenue Next Year60.86%
Revenue Next 2Y57.63%
Revenue Next 3Y55.8%
Revenue Next 5Y46.68%

3.3 Evolution

AXSM Yearly Revenue VS EstimatesAXSM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
AXSM Yearly EPS VS EstimatesAXSM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10 15 20

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

AXSM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
A Price/Forward Earnings ratio of 179.10 indicates a quite expensive valuation of AXSM.
Compared to the rest of the industry, the Price/Forward Earnings ratio of AXSM indicates a somewhat cheap valuation: AXSM is cheaper than 68.75% of the companies listed in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 36.10. AXSM is valued rather expensively when compared to this.
Industry RankSector Rank
PE N/A
Fwd PE 179.1
AXSM Price Earnings VS Forward Price EarningsAXSM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AXSM Per share dataAXSM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
AXSM's earnings are expected to grow with 49.73% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y46.26%
EPS Next 3Y49.73%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AXSM!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AXSOME THERAPEUTICS INC

NASDAQ:AXSM (12/5/2025, 8:04:07 PM)

After market: 149.22 0 (0%)

149.22

+1.18 (+0.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-03 2025-11-03/bmo
Earnings (Next)02-16 2026-02-16/amc
Inst Owners75%
Inst Owner Change-0.78%
Ins Owners1.13%
Ins Owner Change-1.52%
Market Cap7.52B
Revenue(TTM)561.26M
Net Income(TTM)-229.53M
Analysts86.15
Price Target182.31 (22.18%)
Short Float %8.12%
Short Ratio6.69
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.42%
Min EPS beat(2)-6.47%
Max EPS beat(2)13.31%
EPS beat(4)2
Avg EPS beat(4)-8.01%
Min EPS beat(4)-48.67%
Max EPS beat(4)13.31%
EPS beat(8)3
Avg EPS beat(8)-17.43%
EPS beat(12)4
Avg EPS beat(12)-9.71%
EPS beat(16)7
Avg EPS beat(16)-5.43%
Revenue beat(2)2
Avg Revenue beat(2)4.57%
Min Revenue beat(2)3.13%
Max Revenue beat(2)6.01%
Revenue beat(4)2
Avg Revenue beat(4)1.86%
Min Revenue beat(4)-1.03%
Max Revenue beat(4)6.01%
Revenue beat(8)5
Avg Revenue beat(8)1.71%
Revenue beat(12)9
Avg Revenue beat(12)24.39%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.81%
PT rev (3m)1.75%
EPS NQ rev (1m)-13.87%
EPS NQ rev (3m)-16.07%
EPS NY rev (1m)0.29%
EPS NY rev (3m)1.87%
Revenue NQ rev (1m)1.38%
Revenue NQ rev (3m)1.33%
Revenue NY rev (1m)-0.06%
Revenue NY rev (3m)-0.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 179.1
P/S 13.4
P/FCF N/A
P/OCF N/A
P/B 102.03
P/tB 384.59
EV/EBITDA N/A
EPS(TTM)-4.67
EYN/A
EPS(NY)0.83
Fwd EY0.56%
FCF(TTM)-2.01
FCFYN/A
OCF(TTM)-2
OCFYN/A
SpS11.13
BVpS1.46
TBVpS0.39
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -34.3%
ROE -311.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.86%
FCFM N/A
ROA(3y)-49.23%
ROA(5y)-70.3%
ROE(3y)-266.63%
ROE(5y)-345.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.84
Health
Industry RankSector Rank
Debt/Equity 2.61
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.95%
Cap/Sales 0.08%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.57
Quick Ratio 1.5
Altman-Z 4.99
F-Score5
WACC9.22%
ROIC/WACCN/A
Cap/Depr(3y)9.27%
Cap/Depr(5y)133.06%
Cap/Sales(3y)0.56%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.85%
EPS Next Y38.6%
EPS Next 2Y46.26%
EPS Next 3Y49.73%
EPS Next 5Y39.12%
Revenue 1Y (TTM)65.83%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%63.22%
Revenue Next Year60.86%
Revenue Next 2Y57.63%
Revenue Next 3Y55.8%
Revenue Next 5Y46.68%
EBIT growth 1Y29.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.46%
EBIT Next 3Y55.68%
EBIT Next 5Y44.86%
FCF growth 1Y29.12%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y29.05%
OCF growth 3YN/A
OCF growth 5YN/A

AXSOME THERAPEUTICS INC / AXSM FAQ

What is the fundamental rating for AXSM stock?

ChartMill assigns a fundamental rating of 2 / 10 to AXSM.


What is the valuation status of AXSOME THERAPEUTICS INC (AXSM) stock?

ChartMill assigns a valuation rating of 1 / 10 to AXSOME THERAPEUTICS INC (AXSM). This can be considered as Overvalued.


How profitable is AXSOME THERAPEUTICS INC (AXSM) stock?

AXSOME THERAPEUTICS INC (AXSM) has a profitability rating of 1 / 10.


How financially healthy is AXSOME THERAPEUTICS INC?

The financial health rating of AXSOME THERAPEUTICS INC (AXSM) is 2 / 10.